Skip to main content

Table 1 Basic characteristics of the included diabetes RCTs published between 2000 and 2020

From: Twenty-year trends in racial and ethnic enrollment in large diabetes randomized controlled trials

Trial characteristics

Overall RCTs (n = 405)

Year of publication: n (%)

 2000–2004

36 (8.9)

 2005–2009

97 (24.0)

 2010–2014

135 (33.3)

 2015–2020

137 (33.8)

Multi-country trials: n (%)

327 (80.7)

Sample size: median (Q1, Q3)

716 (527, 1246)

Age: median (Q1, Q3), years

58 (55.0, 60.8)

Female proportion: n (%)

46 (39.9, 50.1)

Trial aim: n (%)

 Glycemic control

125 (30.9)

 Management

173 (42.7)

 Complication

105 (25.9)

 Mixed

2 (0.5)

Trial reimbursement for patients: n (%)

0

Outpatient enrolment: n (%)

164 (40.4)

Type of diabetes: n (%)

 

 Type 1 diabetes

16 (4.0)

 Type 2 diabetes

346 (85.4)

 Unspecified

43 (10.6)

Type of randomization: n (%)

 Individual

399 (98.5)

 Cluster

6 (1.5)

Type of intervention: n (%)

 Drug

347 (85.7)

 Lifestyle or education

13 (3.2)

 Device

8 (2.0)

 Others

37 (9.1)

Frequency of intervention: n (%)

 > 1 time/week

325 (80.2)

 1 ~ 4 times/month

11 (2.7)

 > 1 time/ year

3 (0.7)

 Not reported

66 (16.4)

Duration of intervention: median (Q1, Q3), months

6.5 (6.0, 13.5)

Type of follow-up: n (%)

 Face-to-face

231 (57.0)

 Telephone

11 (2.7)

 Others

33 (8.1)

 Not reported

130 (32.2)

Frequency of follow-up: n (%)

 Weekly

6 (1.5)

 Monthly

32 (7.9)

 Yearly

29 (7.2)

 Not reported

338 (83.4)

Duration of follow-up: median (Q1, Q3), months

12 (6.0, 18.0)

Funding sourcen (%)

 Public

67 (16.5)

 Industry

304 (75.0)

 Combination

28 (6.9)

 Not reported

6 (1.6)

  1. RCT randomized controlled trial, Q1 first quartile, Q3 third quartile